Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin crossover study in youth with autism spectrum disorder
2023-506826-36-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in Autism Spectrum Disorder (ASD), sponsored by Oslo University Hospital. Primary endpoints: EEG visual evoked potential neural plasticity and Probabilistic reversal learning task performance. Planned start Jan 2026; status: authorised.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2023-506826-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506826-36-00.